Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692756 | 1.00 | GRIN1 (0.33) | GRIN1XDHCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL501528 | 0.92 | GRIN1 (0.33) | GRIN1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL501939 | 0.87 | MAPT (0.37) | CYP1A2CYP3A4CYP2C9HPGDALOX15 | |
| SCHEMBL12828506 | 0.87 | GRIN1 (0.33) | GRIN1XDH | |
| SCHEMBL501247 | 0.87 | VNN1 (0.34) | GRIN1 | |
| SCHEMBL13956963 | 0.85 | XDH (0.33) | GRIN1XDH | |
| SCHEMBL10204762 | 0.85 | XDH (0.33) | GRIN1XDH | |
| SCHEMBL13955824 | 0.84 | GRIN1 (0.31) | GRIN1 | |
| SCHEMBL502133 | 0.82 | XDH (0.34) | XDHCYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL13486036 | 0.82 | XDH (0.34) | XDHCYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063395-A | Preparation method of anti-AIDS drug Ai Nuowei Lin Zhongjian | 成都艾迪医药技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-118063395-A | Preparation method of anti-AIDS drug Ai Nuowei Lin Zhongjian | 成都艾迪医药技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117466825-A | Preparation method of Ai Nuowei Lin Zhongjian body | 南京艾迪医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117304118-A | Synthesis method of anti-AIDS drug Ai Nuowei forest | 江苏艾迪药业股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-2167476-B1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RES INST CHEM TECH (KR) | 2015-02-25 | — | — | EP | disclosed |
| EP-2167476-B1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RES INST CHEM TECH (KR) | 2015-02-25 | — | — | EP | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8354421-B2 | HIV reverse transcriptase inhibitors | KOREA RESEARCH INSITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-01-15 | — | — | US | disclosed |
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KP) | 2009-03-19 | — | — | US | disclosed |
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KP) | 2009-03-19 | — | — | US | disclosed |
| WO-2009005693-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005674-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005674-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-03-20 | — | — | US | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | GRIN1 1538/4885XDH 667/4885CYP1A2 3032/4885 |
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | GRIN1 1538/4885XDH 667/4885CYP1A2 3032/4885 |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLRMT, POLR2H | GRIN1 2377/4885XDH 786/4885CYP1A2 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.